… study of 1,074,856 outpatients with COVID-19 in Hong Kong showed that molnupiravir use
was … A retrospective cohort study of 920 patients with mild-to-moderate COVID-19 who were …

… We aimed to review the clinical evidence about the safety and efficacy of the molnupiravir
administration … 93.3 percent of adverse effects were mild. The results of this study showed that …

… safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate
COVID… included patients with mild-to-moderate COVID-19 (asymptomatic, mild, and …

… reduced the risk of hospitalization or death by 30% in patients with COVID-19 and has …
mild to moderate COVID-19 [8]. No dose adjustment of molnupiravir is required in cases of mild …

… , randomised clinical trial that investigated molnupiravir for the treatment of mild to moderate
COVID-19 patients at risk of progressing to severe COVID-19 and/or hospitalization. …

… Eligible participants had mild or moderate, laboratory-confirmed COVID-19, with onset of …
molnupiravir in our real-life study was shown to be effective and safe in the high-risk COVID-19 …

… The efficacy and safety of molnupiravir were investigated in the phase III part of the global
MOVe-OUT study in outpatients with mild-to-moderate COVID-19 who were at risk for severe …

… the safety and effectiveness of Nirmatrelvir/Ritonavir versus Molnupiravir in the treatment of
mild-to-moderate COVID-… in cancer patients with COVID-19, Molnupiravir could be safer than …

… The aim of this study was to evaluate the safety profile of molnupiravir in COVID-19 patients.
… the use of three doses of molnupiravir (200, 400 and 800 mg) is safe for COVID-19 patients. …